Status:
COMPLETED
Double-Blinded Randomized Controlled Study Investigating the Efficacy of Exparel (Liposomal Bupivacaine) for Postoperative Pain Relief in Mandibular Third Molar Extractions
Lead Sponsor:
University of Southern California
Conditions:
Post Operative Pain
Eligibility:
All Genders
14+ years
Phase:
PHASE4
Brief Summary
The most prevalent complaint after third molar extractions is pain. There have been many modalities and regimens developed to manage post-operative pain, such as modifications in surgical techniques, ...
Detailed Description
In this study, we will prospectively collect data from all patients receiving bilateral third molar extractions with Exparel versus 0.5% bupivacaine 1:200,000 epinephrine (standard bupivacaine) inject...
Eligibility Criteria
Inclusion
- Patients receiving bilateral mandibular third molar extractions at the Herman Ostrow School of Dentistry by an oral \& maxillofacial surgery resident.
Exclusion
- Patient unable to complete form for four days postoperatively.
- Patient with severe hepatic disease
- Patient with a history of allergy or contraindication to amide-type LA or opioids
- Patient with recent history of antibiotic use within the past thirty days
- Patients with use of long-acting opioids, NSAIDs, aspirin, acetaminophen within 3 days prior to screening.
- Patients who are pregnant.
- Patients receiving additional mandibular teeth extractions.
Key Trial Info
Start Date :
September 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2024
Estimated Enrollment :
73 Patients enrolled
Trial Details
Trial ID
NCT05374499
Start Date
September 1 2022
End Date
May 1 2024
Last Update
March 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Herman Ostrow School of Dentistry of USC
Los Angeles, California, United States, 90089